Washington University School of Medicine: Carcinoma, Squamous Cell trials

The registry lists 11 Carcinoma, Squamous Cell studies with Washington University School of Medicine as lead sponsor. 2 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 5Phase 2 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/2
• 5-Fluorouracil Response and Optimization STudy (The FROST Trial)RecruitingNCT07419464Phase 2
• Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CTTerminatedNCT04685798Not applicableResults posted
• Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyTerminatedNCT03655444Phase 1/2Results posted
• Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)CompletedNCT02573493Phase 2Results posted
• PD 0332991 and Cetuximab in Patients With Incurable SCCHNCompletedNCT02101034Phase 1/2Results posted
• GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell CancerCompletedNCT01553851Phase 2Results posted
• Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck CancerCompletedNCT00671437Phase 2Results posted
• Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT05678348Early Phase 1
• Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
• Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT01716416Phase 1